| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Dermatology,* University Hospital Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Lübeck, University of Lübeck, Lübeck, Germany; Klinik Doctor Kozlowski, München, Germany; and Kyoto University, Kyoto, Japan
The prototypic pituitary hormone prolactin (PRL) exerts a wide variety of bioregulatory effects in mammals and is also found in extrapituitary sites, including murine skin. Here, we show by reverse transcriptase-polymerase chain reaction and immunohistology that, contrary to a previous report, human skin and normal human scalp hair follicles (HFs), in particular, express both PRL and PRL receptors (PRL-R) at the mRNA and protein level. PRL and PRL-R immunoreactivity can be detected in the epithelium of human anagen VI HFs, while the HF mesenchyme is negative. During the HF transformation from growth (anagen) to apoptosis-driven regression (catagen), PRL and PRL-R immunoreactivity appear up-regulated. Treatment of organ-cultured human scalp HFs with high-dose PRL (400 ng/ml) results in a significant inhibition of hair shaft elongation and premature catagen development, along with reduced proliferation and increased apoptosis of hair bulb keratinocytes (Ki-67/terminal dUTP nick-end labeling immunohistomorphometry). This shows that PRL receptors, expressed in HFs, are functional and that human skin and human scalp HFs are both direct targets and sources of PRL. Our data suggest that PRL acts as an autocrine hair growth modulator with catagen-promoting functions and that the hair growth-inhibitory effects of PRL demonstrated here may underlie the as yet ill-understood hair loss in patients with hyper-prolactinemia.
This article has been cited by other articles:
 |
|
 |
|
  E. Gaspar, C. Hardenbicker, E. Bodo, B. Wenzel, Y. Ramot, W. Funk, A. Kromminga, and R. Paus Thyrotropin releasing hormone (TRH): a new player in human hair-growth control FASEB J, February 1, 2010; 24(2): 393 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M.J. Peters, S. Liotiri, E. Bodo, E. Hagen, T. Biro, P. C. Arck, and R. Paus Probing the Effects of Stress Mediators on the Human Hair Follicle: Substance P Holds Central Position Am. J. Pathol., December 1, 2007; 171(6): 1872 - 1886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Telek, T. Biro, E. Bodo, B. I. Toth, I. Borbiro, G. Kunos, and R. Paus Inhibition of human hair follicle growth by endo- and exocannabinoids FASEB J, November 1, 2007; 21(13): 3534 - 3541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Horner, Y. Cazals, R. Guieu, M. Lenoir, and N. Sauze Experimental estrogen-induced hyperprolactinemia results in bone-related hearing loss in the guinea pig Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1224 - E1232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bodo, A. Kromminga, W. Funk, M. Laugsch, U. Duske, W. Jelkmann, and R. Paus Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin FASEB J, October 1, 2007; 21(12): 3346 - 3354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. LeBaron, T. J. Ahonen, M. T. Nevalainen, and H. Rui In Vivo Response-Based Identification of Direct Hormone Target Cell Populations Using High-Density Tissue Arrays Endocrinology, March 1, 2007; 148(3): 989 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A J Craven, A J Nixon, M G Ashby, C J Ormandy, K Blazek, R J Wilkins, and A J Pearson Prolactin delays hair regrowth in mice. J. Endocrinol., November 1, 2006; 191(2): 415 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Ohnemus, M. Uenalan, J. Inzunza, J.-A. Gustafsson, and R. Paus The Hair Follicle as an Estrogen Target and Source Endocr. Rev., October 1, 2006; 27(6): 677 - 706. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
